| Literature DB >> 35735806 |
Márton Dvorák1,2, Ilona Sztancsik2, László Babai2,3, Miklós Tóth1,4,5, Pongrác Ács4,5.
Abstract
BACKGROUND: In the rehabilitation of patients with cardiovascular disease (CVD) and after myocardial infarction (MI), lifestyle modifications-exercise and nutritional therapy, smoking cessation, stress management-are essential and have a major, long-term impact on the overall health of patients.Entities:
Keywords: exercise; heart disease; lifestyle medicine; myocardial infarction; rehabilitation
Year: 2022 PMID: 35735806 PMCID: PMC9224633 DOI: 10.3390/jcdd9060177
Source DB: PubMed Journal: J Cardiovasc Dev Dis ISSN: 2308-3425
Changes in physiological parameters.
| Echocardiography | Baseline | Months 6 | Months 12 |
|---|---|---|---|
| Ao. asc. (mm) | 38 | 29 | 31 |
| LV (mm) | 57 × 31 | 43 × 29 | 56 × 40 |
| AoVmax (m/s) | 1.43 | 1.1 | 1.2 |
| LVOT VTI (cm) | 24 | 19 | 18.8 |
| E/A | 0.78 | 0.88 | 1 |
| DT (ms) | 157 | 216 | 176 |
| APSP (mmHg) | 17 + 5 | 24 + 10 | 20 + 10 |
| TAPSE (mm) | 20 | 22 | 27 |
| EF (%) | 60 | n/a | 58 |
|
| |||
| HR (beat/min) | 73 | 72 | 66 |
| PQ (PR) (ms) | 173 | 169 | 190 |
| QRS (ms) | 95 | 75 | 94 |
| 7.0 | 9.9 | 13.4 | |
| 91.0 | 80.5 | 77.0 | |
| 29.7 | 26.3 | 25.1 | |
| 8.1 | 5.6 | 5.3 |
Ao. asc., ascending aorta; LV, left ventricle; LVOT VTI, left ventricular outflow tract velocity time; E/A ratio, diastolic function; DT, deceleration time; APSP, assisted peak systolic pressure; TAPSE, tricuspid annular plane systolic excursion; EF, ejection fraction; HR, heart rate; BMI, body mass index.
Figure 1Trainings’ rate spent in different HR zones during second half of the program. Maximum HR (100%) was determined from the 220-age formula and intensity zones (here seen with different colors) were calculated from that HR for the patient. In the first row, numbers of the monitored weeks (1–19) are seen.
Changes in medication.
| Baseline | Months 6 | Months 12 | Type of Drugs | |
|---|---|---|---|---|
|
| 100 mg Aspirin protect | 100 mg Aspirin protect | 100 mg Aspirin protect | Antiplatelet agent |
| 75 mg Zyllt | 75 mg Zyllt | Anticoagulant | ||
| 80 mg Atoris | 80 mg Atoris | 40 mg Atoris | Statin | |
| 1 × 2.5 mg, 1 × 1.25 mg Concor | 1 × 2.5 mg, 1 × 1.25 mg Concor | 5 mg Nebilet | Beta blockers | |
| 10 mg Coverex AS | 5 mg Coverex AS | 2.5 mg Coverex AS | ACE inhibitor | |
| 40 mg Pantoprazol | 40 mg Nolpaza | 40 mg Nolpaza | Proton pump inhibitor | |
| 80 mg Adexor Prolong | 80 mg Adexor Prolong | 80 mg Adexor Prolong | Anti-ischemic agent | |
| 2.5 mg Amlodipin | Calcium channel blocker | |||
| 2 × 0.125 mg, 1 × 0.25 mg Frontin | 0.25 mg Frontin | Antidepressant | ||
| 26 mg Erimexol | 26 mg Erimexol | Dopamine agonist |
Medication cessation. Medication reduction.